# BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)

> **NCT01063439** · PHASE2 · UNKNOWN · sponsor: **Inje University** · enrollment: 42 (estimated)

## Conditions studied

- Non Hodgkin's Lymphoma

## Interventions

- **DRUG:** Busulfan, Etoposide, Cytarabine, Melphalan

## Key facts

- **NCT ID:** NCT01063439
- **Lead sponsor:** Inje University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-01
- **Primary completion:** 2014-08
- **Final completion:** 2015-02
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2010-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01063439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01063439, "BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01063439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*